Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CLX Medical has signed a definitive agreement with ThyroTec to acquire ThyroTest, a rapid thyroid stimulating hormone screening device used for the detection of hypothyroidism in adults, a common thyroid disease.
Subscribe to our email newsletter
ThyroTest is FDA cleared and has also achieved CLIA waived status, so the test can be administered in the more than 100,000 CLIA waived doctors’ offices in the US, as well as in any non-waived laboratory, the company said.
ThyroTest, a simple rapid diagnostic test, is a qualitative measurement that allows physicians to screen adult patients for hypothyroidism in approximately 10 minutes with a whole blood sample.
Vera Leonard, CEO of CLX Medical, said: “We are very pleased to announce the definitive agreement for the acquisition of ThyroTest, which we believe is significantly superior to competitive products.
“We believe that the acquisition of ThyroTest will be a major milestone in the development of CLX Medical as we seek to develop long-term value for the company’s shareholders.”